ASHIBIO, INC.
🇺🇸United States
Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Ashibio Inc
- Target Recruit Count
- 10
- Registration Number
- NCT07024407
- Locations
- 🇺🇸
Craig Hospital, Denver, Colorado, United States
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Phase 2
Recruiting
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Ashibio Inc
- Target Recruit Count
- 92
- Registration Number
- NCT06508021
- Locations
- 🇺🇸
University of California San Francisco (UCSF), San Francisco, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Pennsylvania - Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
News
No news found